Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.



СІМЕЙНІ ЛІКАРІ ТА ТЕРАПЕВТИ

НЕВРОЛОГИ, НЕЙРОХІРУРГИ, ЛІКАРІ ЗАГАЛЬНОЇ ПРАКТИКИ, СІМЕЙНІ ЛІКАРІ

КАРДІОЛОГИ, СІМЕЙНІ ЛІКАРІ, РЕВМАТОЛОГИ, НЕВРОЛОГИ, ЕНДОКРИНОЛОГИ

СТОМАТОЛОГИ

ІНФЕКЦІОНІСТИ, СІМЕЙНІ ЛІКАРІ, ПЕДІАТРИ, ГАСТРОЕНТЕРОЛОГИ, ГЕПАТОЛОГИ

ТРАВМАТОЛОГИ

ОНКОЛОГИ, (ОНКО-ГЕМАТОЛОГИ, ХІМІОТЕРАПЕВТИ, МАМОЛОГИ, ОНКО-ХІРУРГИ)

ЕНДОКРИНОЛОГИ, СІМЕЙНІ ЛІКАРІ, ПЕДІАТРИ, КАРДІОЛОГИ ТА ІНШІ СПЕЦІАЛІСТИ

ПЕДІАТРИ ТА СІМЕЙНІ ЛІКАРІ

АНЕСТЕЗІОЛОГИ, ХІРУРГИ

"Kidneys" Том 11, №2, 2022

Back to issue

The value of proteomic studies of the latest markers of kidney damage in the urine to assess the course, progression and complications in patients with CKD

Authors: L.D. Denova
Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine

Categories: Nephrology

Sections: Specialist manual

print version


Summary

Хронічна хвороба нирок (ХХН) є причиною як захворюваності, так і смертності в усьому світі. В Україні ХХН виявляють у 12 % населення. Суттєво погіршують якість життя у пацієнтів із ХХН прогресування фіброзу нирок і порушення мінерального гомеостазу. Основними заходами запобігання прогресуванню ХХН і відстрочення несприятливих наслідків є рання діагностика й лікування. Дефіцит ранніх, неінвазивних біомаркерів негативно впливає на здатність швидко виявляти й лікувати ХХН. У прогресуванні ХХН важливу роль відіграє ураження проксимальних канальців. Є новітні маркери ураження нирок, такі як уромодулін (UMOD), білок Klotho і посттрансляційні модифікації фетуїну А (FtA). Лікування ХХН на ранніх стадіях може покращити функцію нирок і/або сповільнити прогресування ХХН.

Сhronic kidney Disease (CKD) is the cause of both morbidity and mortality worldwide. In Ukraine, 12 % of the population is diagnosed with CKD. Significantly worsen the quality of life in patients with CKD progression of renal fibrosis and impaired mineral homeostasis. Early diagnosis and treatment are the main measures to prevent CKD progression and delay adverse effects. Deficiency of early, non-invasive biomarkers adversely affects the ability to rapidly detect and treat CKD. Proximal tubular lesions play an important role in the progression of CKD. There are new markers of kidney damage, such as uromodulin (UMOD), Klotho protein and post-translational modifications of fetuin A (FtA). Treatment of CKD in the early stages may improve renal function and/or slow the progression of CKD.


Keywords

хронічна хвороба нирок; гіперфосфатемія; уромодулін; протеїн Klotho; фетуїн А

chronic kidney disease; hyperphosphatemia; uromodulinа; Klotho protein; fetuin A


For the full article you need to subscribe to the magazine.


Bibliography

1. Benjamin O., Lappin S.L. End-Stage Renal Disease. 2021 Sep 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022 Jan. PMID: 29763036.
2. Mizdrak M., Kumrić M., Kurir T.T., Božić J. Emerging Biomarkers for Early Detection of Chronic Kidney Disease. J. Pers. Med. 2022 Mar 31. 12(4). 548. doi: 10.3390/jpm12040548. PMID: 35455664. PMCID: PMC9025702.
3. Catanese L., Siwy J., Mavrogeorgis E., Amann K., Mischak H., Beige J., Rupprecht H. A Novel Urinary Proteomics Classifier for Non-Invasive Evaluation of Interstitial Fibrosis and Tubular Atrophy in Chronic Kidney Disease. Proteomes. 2021 Jul 13. 9(3). 32. doi: 10.3390/proteomes9030032. PMID: 34287333. PMCID: PMC8293473.
4. Внутрішня медицина: Підручник для студентів закладів вищої медичної освіти ІІІ–ІV рівня акредитації та лікарів післядипломної освіти на основі рекомендацій доказової медицини / За ред. В.М. Коваленка. Укл.: Н.М. Шуба, О.Г. Несукай, О.П. Борткевич. 3-тє вид., переробл. і доповн. К.: Моріон, 2019. 960 с. + 8 с. кол. вкл. ISBN 978-966-2066-74-6.
5. Yuan Q., Ren Q., Li L., Tan H., Lu M., Tian Y., Huang L., Zhao B., Fu H., Hou F.F., Zhou L., Liu Y. A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling. Nat. Commun. 2022 Jan 21. 13(1). 438. doi: 10.1038/s41467-022-28096-z. PMID: 35064106. PMCID: PMC8782923.
6. Yin T., Chen Y., Tang L., Yuan H., Zeng X., Fu P. Relationship between modifiable lifestyle factors and chronic kidney disease: a bibliometric analysis of top-cited publications from 2011 to 2020. BMC Nephrol. 2022 Mar 25. 23(1). 120. doi: 10.1186/s12882-022-02745-3. PMID: 35337272. PMCID: PMC8957172.
7. Petra E., Siwy J., Vlahou A., Jankowski J. Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease. PLoS One. 2022 Jan 19. 17(1). e0262667. doi: 10.1371/journal.pone.0262667. PMID: 35045102. PMCID: PMC8769332.
8. Šalamon Š., Bevc S., Ekart R., Hojs R., Potočnik U. Polymorphism in the GATM Locus Associated with Dialysis-Independent Chronic Kidney Disease but Not Dialysis-Dependent Kidney Failure. Genes (Basel). 2021 May 28. 12(6). 834. doi: 10.3390/genes12060834. PMID: 34071541. PMCID: PMC8228672.
9. Będzichowska A., Jobs K., Kloc M., Bujnowska A., Kalicki B. The Assessment of the Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children. Biomark Insights. 2021 Apr 20. 16. 11772719211011173. doi: 10.1177/11772719211011173. PMID: 33958853. PMCID: PMC8060753.
10. Gan Y., Zhao M., Feng J. Association of fetuin-A levels and left ventricular diastolic dysfunction in patients on haemodialysis. Int. Urol. Nephrol. 2021 Aug. 53(8). 1689-1694. doi: 10.1007/s11255-021-02796-9. Epub 2021 Mar 6. PMID: 33675483.
11. Panizo S., Martínez-Arias L., Alonso-Montes C., Cannata P., Martín-Carro B., Fernández-Martín J.L., Naves-Díaz M., Carrillo-López N., Cannata-Andía J.B. Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. Int. J. Mol. Sci. 2021 Jan 2. 22(1). 408. doi: 10.3390/ijms22010408. PMID: 33401711. PMCID: PMC7795409.
12. Ludes P.O., de Roquetaillade C., Chousterman B.G., Pottecher J., Mebazaa A. Role of Damage-Associated Molecular Patterns in Septic Acute Kidney Injury, From Injury to Recovery. Front. Immunol. 2021 Mar 1. 12. 606622. doi: 10.3389/fimmu.2021.606622. PMID: 33732235. PMCID: PMC7957065.
13. Lavainne F., Guillot P., Figueres L. Troubles minéraux et osseux dans la maladie rénale chronique: physiopathologie, conséquences et prise en charge [Chronic kidney disease — Mineral bone disorders: Physiopathology and guidelines]. Rev. Med. Interne. 2022 Apr. 43(4). 225-232. French. doi: 10.1016/j.revmed.2022.01.009. Epub 2022 Feb 25. PMID: 35227526.
14. Goyal R., Jialal I. Hyperphosphatemia. 2021 Sep 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022 Jan. PMID: 31869067.
15. Tomo S., Birdi A., Yadav D., Chaturvedi M., Sharma P. Klotho: A Possible Role in the Pathophysiology of Nephrotic Syndrome. EJIFCC. 2022 Apr 11. 33(1). 3-10. PMID: 35645691. PMCID: PMC9092721.
16. Turek M., Stępniewska J., Różański J. The Multifactorial Pathogenesis of Calciphylaxis: A Case Report. Am. J. Case Rep. 2021 Jun 7. 22. e930026. doi: 10.12659/AJCR.930026. PMID: 34097671. PMCID: PMC8197444.
17. Nseir V., Bradauskaite G., Pedroza M., Minimo C., Zaki R., Chewaproug D. A Rare Case of Calciphylaxis in an Orthotopic Liver Transplant Recipient with Acute Kidney Injury. Exp. Clin. Transplant. 2021 Apr. 19(4). 382-385. doi: 10.6002/ect.2017.0123. Epub 2018 Apr 9. PMID: 29633925.
18. Whitehead M., Shanahan C.M. Circulating uromodulin: a cytokine trap for osteoinductive inflammatory mediators in chronic kidney disease? Cardiovasc. Res. 2021 Feb 22. 117(3). 651-652. doi: 10.1093/cvr/cvaa348. PMID: 33367494.
19. Correll V.L., Otto J.J., Risi C.M., Main B.P., Boutros P.C., Kislinger T., Galkin V.E., Nyalwidhe J.O., Semmes O.J., Yang L. Optimization of small extracellular vesicle isolation from expressed prostatic secretions in urine for in-depth proteomic analysis. J. Extracell. Vesicles. 2022 Feb. 11(2). e12184. doi: 10.1002/jev2.12184. PMID: 35119778. PMCID: PMC8815402.
20. Tran A.C., Melchinger H., Weinstein J., Shaw M., Kent C., Perazella M.A., Wilson F.P., Parikh C.R., Moledina D.G. Urine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy. Pract. Lab. Med. 2022 Apr 6. 30. e00271. doi: 10.1016/j.plabm.2022.e00271. PMID: 35465621. PMCID: PMC9018443.
21. Wen Y., Parikh C.R. Current concepts and advances in biomarkers of acute kidney injury. Crit. Rev. Clin. Lab. Sci. 2021 Aug. 58(5). 354-368. doi: 10.1080/10408363.2021.1879000. Epub 2021 Feb 8. PMID: 33556265.
22. Ix J.H., Shlipak M.G. The Promise of Tubule Biomarkers in Kidney Disease: A Review. Am. J. Kidney Dis. 2021 Nov. 78(5). 719-727. doi: 10.1053/j.ajkd.2021.03.026. Epub 2021 May 27. PMID: 34051308. PMCID: PMC8545710.
23. Puthumana J., Thiessen-Philbrook H., Xu L., Coca S.G., Garg A.X., Himmelfarb J., Bhatraju P.K., Ikizler T.A., Siew E.D., Ware L.B., Liu K.D., Go A.S., Kaufman J.S., Kimmel P.L., Chinchilli V.M., Cantley L.G., Parikh C.R. Biomarkers of inflammation and repair in kidney disease progression. J. Clin. Invest. 2021 Feb 1. 131(3). e139927. doi: 10.1172/JCI139927. PMID: 33290282. PMCID: PMC7843225.
24. You R., Zheng H., Xu L., Ma T., Chen G., Xia P., Fan X., Ji P., Wang L., Chen L. Decreased urinary uromodulin is potentially associated with acute kidney injury: a systematic review and meta-analysis. J. Intensive Care. 2021 Nov 15. 9(1). 70. doi: 10.1186/s40560-021-00584-2. PMID: 34782019. PMCID: PMC8591828.
25. Chang C., Obeid W., Thiessen-Philbrook H., Parikh C.R. Sample Processing and Stability for Urine Biomarker Studies. J. Appl. Lab. Med. 2021 Nov 1. 6(6). 1628-1634. doi: 10.1093/jalm/jfab082. PMID: 34414423. PMCID: PMC8561784.
26. Obert L.A., Elmore S.A., Ennulat D., Frazier K.S. A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies. Toxicol. Pathol. 2021 Jul. 49(5). 996-1023. doi: 10.1177/0192623320985045. Epub 2021 Feb 12. PMID: 33576319. PMCID: PMC8195817.
27. Rudnicki M., Siwy J., Wendt R., Lipphardt M., Koziolek M.J., Maixnerova D., Peters B., Kerschbaum J., Leierer J., Neprasova M., Banasik M., Sanz A.B., Perez-Gomez M.V., Ortiz A., Stegmayr B., Tesar V., Mischak H., Beige J., Reich H.N. PERSTIGAN working group. Urine proteomics for prediction of disease progression in patients with IgA nephropathy. Nephrol. Dial. Transplant. 2021 Dec 31. 37(1). 42-52. doi: 10.1093/ndt/gfaa307. PMID: 33313853. PMCID: PMC8719618.
28. Mukhin N., Konoplev G., Oseev A., Schmidt M.P., Stepanova O., Kozyrev A., Dmitriev A., Hirsch S. Label-Free Protein Detection by Micro-Acoustic Biosensor Coupled with Electrical Field Sorting. Theoretical Study in Urine Models. Sensors (Basel). 2021 Apr 6. 21(7). 2555. doi: 10.3390/s21072555. PMID: 33917374. PMCID: PMC8038679.
29. Ascher S.B., Scherzer R., Estrella M.M., Berry J.D., de Lemos J.A., Jotwani V.K., Garimella P.S., Malhotra R., Bullen A.L., Katz R., Ambrosius W.T., Cheung A.K., Chonchol M., Killeen A.A., Ix J.H., Shlipak M.G. SPRINT research group. Kidney tubule health, mineral metabolism, and adverse events in persons with CKD in SPRINT. Nephrol. Dial. Transplant. 2021 Sep 2. gfab255. doi: 10.1093/ndt/gfab255. Epub ahead of print. PMID: 34473302.
30. Bullen A.L., Katz R., Jotwani V., Garimella P.S., Lee A.K., Estrella M.M., Shlipak M.G., Ix J.H. Biomarkers of Kidney Tubule Health, CKD Progression, and Acute Kidney Injury in SPRINT (Systolic Blood Pressure Intervention Trial) Participants. Am. J. Kidney Dis. 2021 Sep. 78(3). 361-368.e1. doi: 10.1053/j.ajkd.2021.01.021. Epub 2021 Apr 20. PMID: 33857535. PMCID: PMC8384678.
31. van Duijl T.T., Ruhaak L.R., Smit N.P.M., Pieterse M.M., Romijn F.P.H.T.M., Dolezal N., Drijfhout J.W., de Fijter J.W., Cobbaert C.M. Development and Provisional Validation of a Multiplex LC-MRM-MS Test for Timely Kidney Injury Detection in Urine. J. Proteome Res. 2021 Dec 3. 20(12). 5304-5314. doi: 10.1021/acs.jproteome.1c00532. Epub 2021 Nov 4. PMID: 34735145. PMCID: PMC8650098.
32. You R., Chen L., Xu L., Zhang D., Li H., Shi X., Zheng Y., Chen L. High Level of Uromodulin Increases the Risk of Hypertension: A Mendelian Randomization Study. Front. Cardiovasc. Med. 2021 Sep 1. 8. 736001. doi: 10.3389/fcvm.2021.736001. PMID: 34540925. PMCID: PMC8440862.
33. Joseph C.B., Mariniello M., Yoshifuji A., Schiano G., Lake J., Marten J., Richmond A., Huffman J.E., Campbell A., Harris S.E., Troyanov S., Cocca M., Robino A., Thériault S., Eckardt K.U., Wuttke M., Cheng Y., Corre T., Kolcic I., Black C., Bruat V., Concas M.P., Sala C., Aeschbacher S., Schaefer F., Bergmann S., Campbell H., Olden M., Polasek O., Porteous D.J., Deary I.J., Madore F., Awadalla P., Girotto G., Ulivi S., Conen D., Wuehl E., Olinger E., Wilson J.F., Bochud M., Köttgen A., Hayward C., Devuyst O. Meta-GWAS Reveals Novel Genetic Variants Associated with Urinary Excretion of Uromodulin. J. Am. Soc. Nephrol. 2022 Mar. 33(3). 511-529. doi: 10.1681/ASN.2021040491. PMID: 35228297. PMCID: PMC8975067.
34. Holzmann-Littig C., Renders L., Steubl D. Uromodulin — a new marker of kidney function? Clin. Nephrol. 2021 Jun. 95(6). 347-349. doi: 10.5414/CN110303. PMID: 33704054.
35. Wang J., Liu L., He K., Gao B., Wang F., Zhao M., Zhang L., On Behalf Of The Chinese Cohort Study Of Chronic Kidney Disease C-Stride. UMOD Polymorphisms Associated with Kidney Function, Serum Uromodulin and Risk of Mortality among Patients with Chronic Kidney Disease, Results from the C-STRIDE Study. Genes (Basel). 2021 Oct 23. 12(11). 1687. doi: 10.3390/genes12111687. PMID: 34828293. PMCID: PMC8620616.
36. Денова Л.Д. Уромодулін як потенційний кандидат-маркер прогнозування перебігу хронічної хвороби нирок. Нирки. 2021. Т. 10. № 4. doi: http://dx.doi.org/10.22141/2307-1257.10.4.2021.247898
37. Franceschini N., Le T.H. Urine Uromodulin and Genetics of its Variation. J. Am. Soc. Nephrol. 2022 Mar. 33(3). 461-462. doi: 10.1681/ASN.2022010027. PMID: 35228296. PMCID: PMC8975060. 
38. Chan J., Svensson M., Tannæs T.M., Waldum-Grevbo B., Jenssen T., Eide I.A. Associations of Serum Uromodulin and Urinary Epidermal Growth Factor with Measured Glomerular Filtration Rate and Interstitial Fibrosis in Kidney Transplantation. Am. J. Nephrol. 2022. 53(2-3). 108-117. doi: 10.1159/000521757. Epub 2022 Feb 1. PMID: 35104815. PMCID: PMC9116601.
39. Then C., Herder C., Then H., Thorand B., Huth C., Heier M., Meisinger C., Peters A., Koenig W., Rathmann W., Roden M., Stumvoll M., Maalmi H., Meitinger T., Lechner A., Scherberich J., Seissler J. Serum uromodulin is inversely associated with biomarkers of subclinical inflammation in the population-based KORA F4 study. Clin. Kidney J. 2020 Sep 6. 14(6). 1618-1625. doi: 10.1093/ckj/sfaa165. PMID: 34221377. PMCID: PMC8248959.
40. Then C., Then H.L., Lechner A., Thorand B., Meisinger C., Heier M., Peters A., Koenig W., Rathmann W., Scherberich J., Seissler J. Serum uromodulin and decline of kidney function in older participants of the population-based KORA F4/FF4 study. Clin. Kidney J. 2020 May 1. 14(1). 205-211. doi: 10.1093/ckj/sfaa032. PMID: 33564420. PMCID: PMC7857794.
41. Mary S., Boder P., Rossitto G., Graham L., Scott K., Flynn A., Kipgen D., Graham D., Delles C. Salt loading decreases urinary excretion and increases intracellular accumulation of uromodulin in stroke-prone spontaneously hypertensive rats. Clin. Sci (Lond). 2021 Dec 22. 135(24). 2749-2761. doi: 10.1042/CS20211017. PMID: 34870708. PMCID: PMC8689196.
42. Alesutan I., Luong T.T.D., Schelski N., Masyout J., Hille S., Schneider M.P., Graham D., Zickler D., Verheyen N., Estepa M., Pasch A., Maerz W., Tomaschitz A., Pilz S., Frey N., Lang F., Delles C., Müller O.J., Pieske B., Eckardt K.U., Scherberich J., Voelkl J. Circulating uromodulin inhibits vascular calcification by interfering with pro-inflammatory cytokine signalling. Cardiovasc. Res. 2021 Feb 22. 117(3). 930-941. doi: 10.1093/cvr/cvaa081. PMID: 32243494.
43. Ponte B., Pruijm M., Ackermann D., Olinger E., Youhanna S., Vogt B., Burnier M., Pechere-Bertschi A., Bochud M., Devuyst O. Uromodulin, Salt, and 24-Hour Blood Pressure in the General Population. Clin. J. Am. Soc. Nephrol. 2021 May 8. 16(5). 787-789. doi: 10.2215/CJN.11230720. Epub 2021 Jan 21. PMID: 33478975. PMCID: PMC8259484.
44. Li S., Wang L., Sun S., Wu Q. Hepsin: a multifunctional transmembrane serine protease in pathobiology. FEBS J. 2021 Sep. 288(18). 5252-5264. doi: 10.1111/febs.15663. Epub 2020 Dec 19. PMID: 33300264.
45. Nanamatsu A., Mori T., Ando F., Furusho T., Mandai S., Susa K., Sohara E., Rai T., Uchida S. Vasopressin Induces Urinary Uromodulin Secretion By Activating PKA (Protein Kinase A). Hypertension. 2021 Jun. 77(6). 1953-1963. doi: 10.1161/HYPERTENSIONAHA.121.17127. Epub 2021 Apr 26. PMID: 33896194.
46. Turner M., Staplin N. UMOD-ulating CKD risk: untangling the relationship between urinary uromodulin, blood pressure, and kidney disease. Kidney Int. 2021 Dec. 100(6). 1168-1170. doi: 10.1016/j.kint.2021.09.019. PMID: 34802557.
47. Singh G., Gohh R., Clark D., Kalra K., Das M., Bradauskaite G., Bleyer A.J., Tanriover B., Chang A.R., Anand P.M. Vignette-Based Reflections to Inform Genetic Testing Policies in Living Kidney Donors. Genes (Basel). 2022 Mar 26. 13(4). 592. doi: 10.3390/genes13040592. PMID: 35456398. PMCID: PMC9025319.
48. Shen F., Liu M., Pei F., Yu L., Yang X. Role of uromodulin and complement activation in the progression of kidney disease. Oncol. Lett. 2021 Dec. 22(6). 829. doi: 10.3892/ol.2021.13090. Epub 2021 Oct 13. PMID: 34691256. PMCID: PMC8527566.
49. Yu L., Pei F., Sun Q., Shen F., Yang X., Hu Z., Liu M. Uromodulin aggravates renal tubulointerstitial injury through activation of the complement pathway in rats. J. Cell. Physiol. 2021 Jul. 236(7). 5012-5021. doi: 10.1002/jcp.30208. Epub 2021 Jan 5. PMID: 33400289.
50. Bai L., Xie Q., Xia M., Gong K., Wang N., Chen Y., Zhao M. The importance of sialic acid, pH and ion concentration on the interaction of uromodulin and complement factor H. J. Cell. Mol. Med. 2021 May. 25(9). 4316-4325. doi: 10.1111/jcmm.16492. Epub 2021 Mar 31. PMID: 33788378. PMCID: PMC8093974.
51. Stsiapanava A., Xu C., Nishio S., Han L., Yamakawa N., Carroni M., Tunyasuvunakool K., Jumper J., de Sanctis D., Wu B., Jovine L. Structure of the decoy module of human glycoprotein 2 and uromodulin and its interaction with bacterial adhesin FimH. Nat. Struct. Mol. Biol. 2022 Mar. 29(3). 190-193. doi: 10.1038/s41594-022-00729-3. Epub 2022 Mar 10. PMID: 35273390. PMCID: PMC8930769.
52. Micanovic R., LaFavers K.A., Patidar K.R., Ghabril M.S., Doud E.H., Mosley A.L., Sabo A.R., Khan S., El-Achkar T.M. The kidney releases a nonpolymerizing form of uromodulin in the urine and circulation that retains the external hydrophobic patch domain. Am. J. Physiol. Renal. Physiol. 2022 Apr 1. 322(4). F403-F418. doi: 10.1152/ajprenal.00322.2021. Epub 2022 Jan 31. PMID: 35100812. PMCID: PMC8934678.
53. Abdelsalam M., Motawea M., Kyrillos F., Abdel-Razik A., Zaki M.E.S., Abdel-Wahab A. Study of Uromodulin Gene Polymorphism in Egyptian Patients with End-Stage Renal Disease. Saudi J. Kidney Dis. Transpl. 2021 Jan-Feb. 32(1). 157-162. doi: 10.4103/1319-2442.318517. PMID: 34145125.
54. Mansour S.G., Liu C., Jia Y., Reese P.P., Hall I.E., El-Achkar T.M., LaFavers K.A., Obeid W., Rosenberg A.Z., Daneshpajouhnejad P., Doshi M.D., Akalin E., Bromberg J.S., Harhay M.N., Mohan S., Muthukumar T., Schröppel B., Singh P., El-Khoury J.M., Weng F.L., Thiessen-Philbrook H.R., Parikh C.R. Uromodulin to Osteopontin Ratio in Deceased Donor Urine Is Associated With Kidney Graft Outcomes. Transplantation. 2021 Apr 1. 105(4). 876-885. doi: 10.1097/TP.0000000000003299. PMID: 32769629. PMCID: PMC8805736.
55. Usui R., Ogawa T., Takahashi H., Iwasaki C., Koike M., Morito T., Hatano M., Nitta K. Serum uromodulin is a novel renal function marker in the Japanese population. Clin. Exp. Nephrol. 2021 Jan. 25(1). 28-36. doi: 10.1007/s10157-020-01964-y. Epub 2020 Sep 11. PMID: 32915368.
56. Ponte B., Sadler M.C., Olinger E., Vollenweider P., Bochud M., Padmanabhan S., Hayward C., Kutalik Z., Devuyst O. Mendelian randomization to assess causality between uromodulin, blood pressure and chronic kidney disease. Kidney Int. 2021 Dec. 100(6). 1282-1291. doi: 10.1016/j.kint.2021.08.032. Epub 2021 Oct 9. PMID: 34634361.
57. Enko D., Meinitzer A., Scherberich J.E., März W., Herrmann M., Artinger K., Rosenkranz A.R., Zitta S. Individual uromodulin serum concentration is independent of glomerular filtration rate in healthy kidney donors. Clin. Chem. Lab. Med. 2020 Oct 13. 59(3). 563-570. doi: 10.1515/cclm-2020-0894. PMID: 33048833.
58. Cansever H.N., Sari F., Cevikol C., Cetinkaya R., Süleymanlar G., Ersoy F. Serum uromodulin levels, MR imaging findings, and their relationship with eGFR-based CKD staging in ADPKD patients. Int. Urol. Nephrol. 2021 Jul. 53(7). 1383-1389. doi: 10.1007/s11255-020-02730-5. Epub 2021 Jan 3. PMID: 33389516.
59. Jie C., Yi-Ying Y., Miao C. Correlation of serum uromodulin levels with renal fibrosis and renal function progression in patients with CKD. Pak. J. Pharm. Sci. 2021 Nov. 34(6(Special)). 2417-2422. PMID: 35039253.
60. Yazdani B., Delgado G.E., Scharnagl H., Krämer B.K., Drexel H., März W., Scherberich J.E., Leiherer A., Kleber M.E. Combined Use of Serum Uromodulin and eGFR to Estimate Mortality Risk. Front. Med. (Lausanne). 2021 Sep 8. 8. 723546. doi: 10.3389/fmed.2021.723546. PMID: 34568379. PMCID: PMC8455921.
61. Then C., Herder C., Thorand B., Sujana C., Heier M., Meisinger C., Peters A., Koenig W., Rathmann W., Roden M., Stumvoll M., Maalmi H., Then H., Ferrari U., Scherberich J., Seissler J. KORA-Study Group. Association of serum uromodulin with adipokines in dependence of type 2 diabetes. Cytokine. 2022 Feb. 150. 155786. doi: 10.1016/j.cyto.2021.155786. Epub 2021 Dec 15. PMID: 34920231.
62. LaFavers K. Disruption of Kidney-Immune System Crosstalk in Sepsis with Acute Kidney Injury: Lessons Learned from Animal Models and Their Application to Human Health. Int. J. Mol. Sci. 2022 Feb 1. 23(3). 1702. doi: 10.3390/ijms23031702. PMID: 35163625. PMCID: PMC8835938.
63. Jain R.B., Ducatman A. Associations between the concentrations of α-klotho and selected perfluoroalkyl substances in the presence of eGFR based kidney function and albuminuria: Data for US adults aged 40–79 years. Sci Total Environ. 2022 May 17. 155994. doi: 10.1016/j.scitotenv.2022.155994. Epub ahead of print. PMID: 35595139.
64. Močnik M., Marčun Varda N. Current Knowledge of Selected Cardiovascular Biomarkers in Pediatrics: Kidney Injury Molecule-1, Salusin-α and -β, Uromodulin, and Adropin. Children (Basel). 2022 Jan 13. 9(1). 102. doi: 10.3390/children9010102. PMID: 35053727. PMCID: PMC8774650.
65. Ray S.K., Masarkar N., Mukherjee S. Implications of Klotho Protein for Managing Kidney Disease — an Emerging Role in Therapeutics and Molecular Medicine. Curr. Mol. Med. 2021. 21(6). 484-494. doi: 10.2174/1566524020666201120143313. PMID: 33222666.
66. Noonin C., Peerapen P., Yoodee S., Kapincharanon C., Kanlaya R., Thongboonkerd V. Systematic analysis of modulating activities of native human urinary Tamm-Horsfall protein on calcium oxalate crystallization, growth, aggregation, crystal-cell adhesion and invasion through extracellular matrix. Chem. Biol. Interact. 2022 Apr 25. 357. 109879. doi: 10.1016/j.cbi.2022.109879. Epub 2022 Mar 6. PMID: 35263610.
67. Hasan F.T., Mohey M.A. Association of genetic polymorphism and expression of UMOD gene and chronic kidney disease. Wiad. Lek. 2021. 74(9 cz. 2). 2297-2300. PMID: 34824175.
68. Yang Y., Hong S., Li C., Zhang J., Hu H., Chen X., Jiang K., Sun F., Wang Q., Wang S. Proteomic analysis reveals some common proteins in the kidney stone matrix. PeerJ. 2021 Jul 27. 9. e11872. doi: 10.7717/peerj.11872. PMID: 34395096. PMCID: PMC8323604.
69. Wang Y., Du M.F., Yao S., Zou T., Zhang X.Y., Hu G.L., Chu C., Liao Y.Y., Chen C., Wang D., Ma Q., Wang K.K., Sun Y., Niu Z.J., Yan R.C., Yan Y., Zhou H.W., Jia H., Gao W.H., Li H., Li C.H., Chen F.Y., Gao K., Zhang J., Safirstein R., Wang F., Yang T.L., Mu J.J. Associations of Serum Uromodulin and Its Genetic Variants With Blood Pressure and Hypertension in Chinese Adults. Front. Cardiovasc. Med. 2021 Nov 17. 8. 710023. doi: 10.3389/fcvm.2021.710023. PMID: 34869624. PMCID: PMC8635522.
70. Du M.F., Yao S., Zou T., Mu J.J., Zhang X.Y., Hu G.L., Chu C., Jia H., Liao Y.Y., Chen C., Wang D., Ma Q., Yan Y., Wang K.K., Sun Y., Niu Z.J., Yan R.C., Zhang X., Zhou H.W., Gao W.H., Li H., Li C.H., Gao K., Zhang J., Yang T.L., Wang Y. Associations of plasma uromodulin and genetic variants with blood pressure responses to dietary salt interventions. J. Clin. Hypertens. (Greenwich). 2021 Oct. 23(10). 1897-1906. doi: 10.1111/jch.14347. Epub 2021 Aug 7. PMID: 34363725. PMCID: PMC8678750.
71. Boder P., Mary S., Mark P.B., Leiper J., Dominiczak A.F., Padmanabhan S., Rampoldi L., Delles C. Mechanistic interactions of uromodulin with the thick ascending limb: perspectives in physiology and hypertension. J. Hypertens. 2021 Aug 1. 39(8). 1490-1504. doi: 10.1097/HJH.0000000000002861. PMID: 34187999. PMCID: PMC7611110.
72. Utami S.B., Endo R., Hamada T., Notsu T., Minato H., Komatsu K., Nakayama Y., Shirayoshi Y., Yamamoto K., Okada S., Ninomiya H., Otuki A., Hisatome I. Hsp70 promotes maturation of uromodulin mutants that cause familial juvenile hyperuricemic nephropathy and suppresses cellular damage. Clin. Exp. Nephrol. 2022 Jun. 26(6). 522-529. doi: 10.1007/s10157-022-02196-y. Epub 2022 Feb 25. PMID: 35212881.
73. Shamam Y.M., Hashmi M.F. Autosomal Dominant Tubulointerstitial Kidney Disease. 2022 Apr 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022 Jan. PMID: 33760469.
74. Bleyer A.J., Wolf M.T., Kidd K.O., Zivna M., Kmoch S. Autosomal dominant tubulointerstitial kidney disease: more than just HNF1β. Pediatr. Nephrol. 2022 May. 37(5). 933-946. doi: 10.1007/s00467-021-05118-4. Epub 2021 May 22. PMID: 34021396. PMCID: PMC8722360.
75. Wang D., Qiu Y., Fan J., Liu Y., Chen W., Li Z., Chen W., Wang X. Upregulation of C/EBP Homologous Protein induced by ER Stress Mediates Epithelial to Myofibroblast Transformation in ADTKD-UMOD. Int. J. Med. Sci. 2022 Jan 24. 19(2). 364-376. doi: 10.7150/ijms.65036. PMID: 35165522. PMCID: PMC8795802.
76. Schaeffer C., Devuyst O., Rampoldi L. Uromodulin: Roles in Health and Disease. Annual Rev. Physiol. 2021 Feb 10. 83. 477-501. doi: 10.1146/annurev-physiol-031620-092817. PMID: 33566673.
77. Li Y., Cheng Y., Consolato F., Schiano G., Chong M.R., Pietzner M., Nguyen N.Q.H., Scherer N., Biggs M.L., Kleber M.E., Haug S., Göçmen B., Pigeyre M., Sekula P., Steinbrenner I., Schlosser P., Joseph C.B., Brody J.A., Grams M.E., Hayward C., Schultheiss U.T., Krämer B.K., Kronenberg F., Peters A., Seissler J., Steubl D., Then C., Wuttke M., März W., Eckardt K.U., Gieger C., Boerwinkle E., Psaty B.M., Coresh J., Oefner P.J., Pare G., Langenberg C., Scherberich J.E., Yu B., Akilesh S., Devuyst O., Rampoldi L., Köttgen A. Genome-wide studies reveal factors associated with circulating uromodulin and its relations with complex diseases. JCI Insight. 2022 Apr 21. e157035. doi: 10.1172/jci.insight.157035. Epub ahead of print. PMID: 35446786.
78. Beenken A., Al-Awqati Q. Uromodulin fights UTI with sugars. Kidney Int. 2021 May. 99(5). 1057-1059. doi: 10.1016/j.kint.2020.12.035. Epub 2021 Feb 5. PMID: 33549589.
79. Li H., Kostel S.A., DiMartino S.E., Hashemi Gheinani A., Froehlich J.W., Lee R.S. Uromodulin Isolation and Its N-Glycosylation Analysis by NanoLC-MS/MS. J. Proteome Res. 2021 May 7. 20(5). 2662-2672. doi: 10.1021/acs.jproteome.0c01053. Epub 2021 Mar 2. PMID: 33650863.
80. Patabandige M.W., Go E.P., Desaire H. Clinically Viable Assay for Monitoring Uromodulin Glycosylation. J. Am. Soc. Mass Spectrom. 2021 Feb 3. 32(2). 436-443. doi: 10.1021/jasms.0c00317. Epub 2020 Dec 10. PMID: 33301684. PMCID: PMC8541689.
81. Liu Q., Li S., Yu L., Yin X., Liu X., Ye J., Lu G. CCL5 Suppresses Klotho Expression via p-STAT3/DNA Methyltransferase1-Mediated Promoter Hypermethylation. Front. Physiol. 2022 Mar 1. 13. 856088. doi: 10.3389/fphys.2022.856088. PMID: 35299661. PMCID: PMC8922032.
82. Gupta M., Orozco G., Rao M., Gedaly R., Malluche H.H., Neyra J.A. The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation. Front. Med. (Lau–sanne). 2022 May 6. 9. 803016. doi: 10.3389/fmed.2022.803016. PMID: 35602513. PMCID: PMC9121872.
83. Wu S.E., Chen W.L. Soluble Klotho as an effective biomarker to characterize inflammatory states. Ann. Med. 2022 Dec. 54(1). 1520-1529. doi: 10.1080/07853890.2022.2077428. PMID: 35603960.
84. Jin D., Jia M., Xie Y., Lin L., Qiu H., Lu G. Impact of Klotho on the expression of SRGAP2a in podocytes in diabetic nephropathy. BMC Nephrol. 2022 Apr 18. 23(1). 151. doi: 10.1186/s12882-022-02765-z. PMID: 35436879. PMCID: PMC9014571.
85. Kale A., Sankrityayan H., Anders H.J., Gaikwad A.B. Klotho in kidney diseases: A crosstalk between the renin-angiotensin system and endoplasmic reticulum stress. Nephrol. Dial. Transplant. 2021 Nov 26. gfab340. doi: 10.1093/ndt/gfab340. Epub ahead of print. PMID: 34850136.
86. Нестерова А.А., Глинка Е.Ю., Тюренков И.Н., Перфилова В.Н. Белок Клото — универсальный регулятор физиологических процессов в организме. Успехи физиологических наук. 2020. Т. 51. № 2. С. 88-104. DOI: 10.31857/S0301179820020083.
87. Li S., Kong J., Yu L., Liu Q. Abnormally decreased renal Klotho is linked to endoplasmic reticulum-associated degradation in mice. Int. J. Med. Sci. 2022 Jan 9. 19(2). 321-330. doi: 10.7150/ijms.68137. PMID: 35165517. PMCID: PMC8795804.
88. Ciardullo S., Perseghin G. Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes. Acta Diabetol. 2022 Jun. 59(6). 803-809. doi: 10.1007/s00592-022-01865-4. Epub 2022 Mar 14. PMID: 35286490. PMCID: PMC9085659.
89. Hu M.C., Moe O.W. Phosphate and Cellular Senescence. Adv. Exp. Med. Biol. 2022. 1362. 55-72. doi: 10.1007/978-3-030-91623-7_7. PMID: 35288873.
90. Du C., Wang X., Wu Y., Liao W., Xiong J., Zhu Y., Liu C., Han W., Wang Y., Han S., Chen S., Xu Y., Wang S., Wang F., Yang K., Zhao J., Wang J. Renal Klotho and inorganic phosphate are extrinsic factors that antagonistically regulate hematopoietic stem cell maintenance. Cell. Rep. 2022 Feb 15. 38(7). 110392. doi: 10.1016/j.celrep.2022.110392. PMID: 35172146.
91. Buchanan S., Combet E., Stenvinkel P., Shiels P.G. Klotho, Aging, and the Failing Kidney. Front. Endocrinol. (Lausanne). 2020 Aug 27. 11. 560. doi: 10.3389/fendo.2020.00560. PMID: 32982966. PMCID: PMC7481361.
92. Zhao M., Murakami S., Matsumaru D., Kawauchi T., Nabeshima Y.I., Motohashi H. NRF2 pathway activation attenuates ageing-related renal phenotypes due to α-klotho deficiency. J. Biochem. 2022 May 11. 171(5). 579-589. doi: 10.1093/jb/mvac014. PMID: 35137128.
93. Lehtihet M., Stephanou C., Börjesson A., Bhuiyan H., Pohanka A., Ekström L. Studies of IGF-I and Klotho Protein in Relation to Anabolic-Androgenic Steroid and Growth Hormone Administrations. Front. Sports Act. Living. 2022 Mar 31. 4. 829940. doi: 10.3389/fspor.2022.829940. PMID: 35434614. PMCID: PMC9008280.
94. Desbiens L.C., Sidibé A., Ung R.V., Mac-Way F. FGF23-Klotho Axis and Fractures in Patients Without and With Early CKD: A Case-Cohort Analysis of CARTaGENE. J. Clin. Endocrinol. Metab. 2022 May 17. 107(6). e2502-e2512. doi: 10.1210/clinem/dgac071. PMID: 35139204. PMCID: PMC9113817.
95. Wu Q., Fan W., Zhong X., Zhang L., Niu J., Gu Y. Klotho/FGF23 and Wnt in SHPT associated with CKD via regulating miR-29a. Am. J. Transl. Res. 2022 Feb 15. 14(2). 876-887. PMID: 35273691. PMCID: PMC8902549.
96. Isakova T., Yanucil C., Faul C. A Klotho-Derived Peptide as a Possible Novel Drug to Prevent Kidney Fibrosis. Am. J. Kidney Dis. 2022 Apr 22. S0272-6386(22)00620-5. doi: 10.1053/j.ajkd.2022.03.006. Epub ahead of print. PMID: 35469964.
97. Valiño-Rivas L., Cuarental L., Ceballos M.I., Pintor-Chocano A., Perez-Gomez M.V., Sanz A.B., Ortiz A., Sanchez-Niño M.D. Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis. Kidney Int. 2022 Jun. 101(6). 1200-1215. doi: 10.1016/j.kint.2022.02.028. Epub 2022 Mar 23. PMID: 35337892.
98. Rudloff S., Jahnen-Dechent W., Huynh-Do U. Tissue chaperoning-the expanded functions of fetuin-A beyond inhibition of systemic calcification. Pflugers Arch. 2022 Apr 11. 1-14. doi: 10.1007/s00424-022-02688-6. Epub ahead of print. PMID: 35403906. PMCID: PMC8995415.
99. Icer M.A., Yıldıran H. Effects of fetuin-A with diverse functions and multiple mechanisms on human health. Clin. Biochem. 2021 Feb. 88. 1-10. doi: 10.1016/j.clinbiochem.2020.11.004. Epub 2020 Nov 25. PMID: 33245873.
100. Bassey P.E., Numthavaj P., Rattanasiri S., Sritara P., McEvoy M., Ongphiphadhanakul B., Thakkinstian A. Causal association pathways between fetuin-A and kidney function: a mediation analysis. J. Int. Med. Res. 2022 Apr. 50(4). 3000605221082874. doi: 10.1177/03000605221082874. PMID: 35435033. PMCID: PMC9019358.
101. Magalhães P., Zürbig P., Mischak H., Schleicher E. Urinary fetuin-A peptides as a new marker for impaired kidney function in patients with type 2 diabetes. Clin. Kidney J. 2020 Oct 23. 14(1). 269-276. doi: 10.1093/ckj/sfaa176. PMID: 33564428. PMCID: PMC7857838.
102. Kovářová M., Kalbacher H., Peter A., Häring H.U., Didangelos T., Stefan N., Birkenfeld A., Schleicher E., Kantartzis K. Detection and Characterization of Phosphorylation, Glycosylation, and Fatty Acid Bound to Fetuin A in Human Blood. J. Clin. Med. 2021 Jan 22. 10(3). 411. doi: 10.3390/jcm10030411. PMID: 33499061. PMCID: PMC7865524.
103. Umapathy D., Subramanyam P.V., Krishnamoorthy E., Viswanathan V., Ramkumar K.M. Association of Fetuin-A with Thr256Ser exon polymorphism of α2-Heremans Schmid Glycoprotein (AHSG) gene in type 2 diabetic patients with overt nephropathy. J. Diabetes Complications. 2022 Jan. 36(1).108074. doi: 10.1016/j.jdiacomp.2021.108074. Epub 2021 Oct 8. PMID: 34774416.
104. Jirak P., Stechemesser L., Moré E., Franzen M., Topf A., Mirna M., Paar V., Pistulli R., Kretzschmar D., Wernly B., Hoppe U.C., Lichtenauer M., Salmhofer H. Clinical implications of fetuin-A. Adv. Clin. Chem. 2019. 89.79-130. doi: 10.1016/bs.acc.2018.12.003. Epub 2019 Feb 8. PMID: 30797472.
105. Birukov A., Polemiti E., Jäger S., Stefan N., Schulze M.B. Fetuin-A and risk of diabetes-related vascular complications: a prospective study. Cardiovasc. Diabetol. 2022 Jan 8. 21(1). 6. doi: 10.1186/s12933-021-01439-8. PMID: 34998417. PMCID: PMC8742328.
106. Zhou Z., Chen H., Sun M., Jin H., Ju H. Fetuin-A to adiponectin ratio is an independent indicator of subclinical atherosclerosis in patients with newly diagnosed type 2 diabetes mellitus. J. Diabetes Complications. 2022 Jan. 36(1). 108102. doi: 10.1016/j.jdiacomp.2021.108102. Epub 2021 Dec 3. PMID: 34887185.
107. Kothari V., Babu J.R., Mathews S.T. AMP activated kinase negatively regulates hepatic Fetuin-A via p38 MAPK-C/EBPβ/E3 Ubiquitin Ligase Signaling pathway. PLoS One. 2022 May 6. 17(5). e0266472. doi: 10.1371/journal.pone.0266472. PMID: 35522655. PMCID: PMC9075660.
108. Luís C., Soares R., Baylina P., Fernandes R. Underestimated Prediabetic Biomarkers: Are We Blind to Their Strategy? Front. Endocrinol. (Lausanne). 2022 Mar 7. 13. 805837. doi: 10.3389/fendo.2022.805837. PMID: 35321333. PMCID: PMC8936175.
109. Ahn M.B., Kim S.K., Kim S.H., Cho W.K., Suh J.S., Cho K.S., Suh B.K., Jung M.H. Clinical Significance of the Fetuin-A-to-Adiponectin Ratio in Obese Children and Adolescents with Diabetes Mellitus. Children (Basel). 2021 Dec 8. 8(12). 1155. doi: 10.3390/children8121155. PMID: 34943350. PMCID: PMC8699833.
110. Harbuwono D.S., Sazli B.I., Kurniawan F., Darmowidjojo B., Koesnoe S., Tahapary D.L. The impact of Ramadan fasting on Fetuin-A level in type 2 diabetes mellitus. Heliyon. 2021 May 15. 7(5). e06773. doi: 10.1016/j.heliyon.2021.e06773. PMID: 34041376. PMCID: PMC8141768.
111. Lőrincz H., Csige I., Harangi M., Szentpéteri A., Seres I., Szabó Z., Paragh G., Somodi S. Low Levels of Serum Fetuin-A and Retinol-Binding Protein 4 Correlate with Lipoprotein Subfractions in Morbid Obese and Lean Non-Diabetic Subjects. Life (Basel). 2021 Aug 27. 11(9). 881. doi: 10.3390/life11090881. PMID: 34575030. PMCID: PMC8471801.
112. Susairaj P., Snehalatha C., Nanditha A., Satheesh K., Raghavan A., Vinitha R., Ramachandran A. Analysis of an Indian diabetes prevention programme on association of adipokines and a hepatokine with incident diabetes. Sci Rep. 2021 Oct 13. 11(1). 20327. doi: 10.1038/s41598-021-99784-x. PMID: 34645898. PMCID: PMC8514464.
113. Högstedt A., Farnebo S., Tesselaar E., Ghafouri B. Investigation of proteins important for microcirculation using in vivo microdialysis after glucose provocation: a proteomic study. Sci Rep. 2021 Sep 27. 11(1). 19093. doi: 10.1038/s41598-021-98672-8. PMID: 34580391. PMCID: PMC8476624.
114. Khan S.R., Canales B.K., Dominguez-Gutierrez P.R. Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation. Nat. Rev. Nephrol. 2021 Jun. 17(6). 417-433. doi: 10.1038/s41581-020-00392-1. Epub 2021 Jan 29. PMID: 33514941. 
115. Chattopadhyay D., Das S., Guria S., Basu S., Mukherjee S. Fetuin-A regulates adipose tissue macrophage content and activation in insulin resistant mice through MCP-1 and iNOS: involvement of IFNγ-JAK2-STAT1 pathway. Biochem. J. 2021 Nov 26. 478(22). 4027-4043. doi: 10.1042/BCJ20210442. PMID: 34724561.
116. Ghadimi M., Foroughi F., Hashemipour S., Nooshabadi M.R., Ahmadi M.H., Yari M.G., Kavianpour M., Haghighian H.K. Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial. Diabetol. Metab. Syndr. 2021 Feb 5. 13(1). 16. doi: 10.1186/s13098-021-00633-8. PMID: 33546744. PMCID: PMC7866694.
117. Werida R.H., Abou-Madawy S., Abdelsalam M., Helmy M.W. Omega 3 fatty acids effect on the vascular calcification biomarkers fetuin A and osteoprotegerin in hemodialysis patients. Clin. Exp. Med. 2022 May. 22(2). 301-310. doi: 10.1007/s10238-021-00740-w. Epub 2021 Jul 20. PMID: 34286397.
118. Anzai F., Karasawa T., Komada T., Yamada N., Miura Y., Sampilvanjil A., Baatarjav C., Fujimura K., Matsumura T., Tago K., Kurosu H., Takeishi Y., Kuro-O M., Takahashi M. Calciprotein Particles Induce IL-1β/α-Mediated Inflammation through NLRP3 Inflammasome-Dependent and -Independent Mechanisms. Immunohorizons. 2021 Jul 29. 5(7). 602-614. doi: 10.4049/immunohorizons.2100066. PMID: 34326201.
119. Chen W., Fitzpatrick J., Monroy-Trujillo J.M., Sozio S.M., Jaar B.G., Estrella M.M., Serrano J., Anokhina V., Miller B.L., Melamed M.L., Bushinsky D.A., Parekh R.S. Associations of Serum Calciprotein Particle Size and Transformation Time With Arterial Calcification, Arterial Stiffness, and Mortality in Incident Hemodialysis Patients. Am. J. Kidney Dis. 2021 Mar. 77(3). 346-354. doi: 10.1053/j.ajkd.2020.05.031. Epub 2020 Aug 13. PMID: 32800846. PMCID: PMC7881044.
120. Janus S.E., Hajjari J., Chami T., Mously H., Badhwar A.K., Karnib M., Carneiro H., Rahman M., Al-Kindi S.G. Multi-Variable Biomarker Approach in Identifying Incident Heart Failure in Chronic Kidney Disease Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Eur. J. Heart Fail. 2022 May 19. doi: 10.1002/ejhf.2543. Epub ahead of print. PMID: 35587997.
121. Tiong M.K., Smith E.R., Pascoe E.M., Elder G.J., Lioufas N.M., Pedagogos E., Hawley C.M., Valks A., Holt S.G., Hewitson T.D., Toussaint N.D. Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3–4 CKD — results from a placebo-controlled randomised trial. Nephrol. Dial. Transplant. 2022 Feb 25. gfac043. doi: 10.1093/ndt/gfac043. Epub ahead of print. PMID: 35212735.
122. Sevinc C., Yilmaz G., Ustundag S. The relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosis. Ren. Fail. 2021 Dec. 43(1). 1349-1358. doi: 10.1080/0886022X.2021.1969248. PMID: 34583616. PMCID: PMC8491735.
123. Kuro-O M. Klotho and calciprotein particles as therapeutic targets against accelerated ageing. Clin. Sci (Lond). 2021 Aug 13. 135(15). 1915-1927. doi: 10.1042/CS20201453. PMID: 34374422. PMCID: PMC8355631.
124. Cui Z., Li Y., Liu G., Jiang Y. miR-103a-3p Silencing Ameliorates Calcium Oxalate Deposition in Rat Kidney by Activating the UMOD/TRPV5 Axis. Dis. Markers. 2022 Feb 23. 2022. 2602717. doi: 10.1155/2022/2602717. PMID: 35251369. PMCID: PMC8890864.
125. Poloczek J., Kazura W., Kwaśnicka E., Gumprecht J., Jochem J., Stygar D. Effects of Bariatric Surgeries on Fetuin-A, Selenoprotein P, Angiopoietin-Like Protein 6, and Fibroblast Growth Factor 21 Concentration. J. Diabetes Res. 2021 Aug 6. 2021. 5527107. doi: 10.1155/2021/5527107. PMID: 34414240. PMCID: PMC8369187.
126. Koeppert S., Ghallab A., Peglow S., Winkler C.F., Graeber S., Büscher A., Hengstler J.G., Jahnen-Dechent W. Live Imaging of Calciprotein Particle Clearance and Receptor Mediated Uptake: Role of Calciprotein Monomers. Front. Cell. Dev. Biol. 2021 Apr 29. 9. 633925. doi: 10.3389/fcell.2021.633925. PMID: 33996793. PMCID: PMC8116800.
127. Alshahawey M., El Borolossy R., El Wakeel L., Elsaid T., Sabri N.A. The impact of cholecalciferol on markers of vascular calcification in hemodialysis patients: A randomized placebo controlled study. Nutr. Metab. Cardiovasc. Dis. 2021 Feb 8. 31(2). 626-633. doi: 10.1016/j.numecd.2020.09.014. Epub 2020 Sep 21. PMID: 33594986.
128. Tiong M.K., Krishnasamy R., Smith E.R., Hutchison C.A., Ryan E.G., Pascoe E.M., Hawley C.M., Hewitson T.D., Jardine M.J., Roberts M.A., Cho Y., Wong M.G., Heath A., Nelson C.L., Sen S., Mount P.F., Vergara L.A., Paul-Brent P.A., Johnson D.W., Toussaint N.D. Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. Hemodial. Int. 2021 Mar 28. doi: 10.1111/hdi.12924. Epub ahead of print. PMID: 33779046.
129. Werida R.H., Abou-Madawy S., Abdelsalam M., Helmy M.W. Omega 3 fatty acids effect on the vascular calcification biomarkers fetuin A and osteoprotegerin in hemodialysis patients. Clin. Exp. Med. 2022 May. 22(2). 301-310. doi: 10.1007/s10238-021-00740-w. Epub 2021 Jul 20. PMID: 34286397.
130. Roca-Tey R., Ramírez de Arellano M., González-Oliva J.C., Roda A., Samon R., Ibrik O., Ugalde-Altamirano J., Viladoms J., Calls J. Is fetuin-A a biomarker of dialysis access dysfunction? J. Vasc. Access. 2021 Jul 29. 11297298211035846. doi: 10.1177/11297298211035846. Epub ahead of print. PMID: 34325543.
131. Kuro-O M. Phosphate as a Pathogen of Arteriosclerosis and Aging. J. Atheroscler. Thromb. 2021 Mar 1. 28(3). 203-213. doi: 10.5551/jat.RV17045. Epub 2020 Oct 8. PMID: 33028781. PMCID: PMC8048948.
132. Fernández P., Douthat W., Castellano M., Cardozo G., Garay G., de Arteaga J., Chiurchiu C., de la Fuente J. Biomarkers of bone and mineral disorders (FGF-23, fetuin-A) and vascular calcification scores as predictive tools for cardiovascular death in dialysis patients, at 10 years of follow-up. Medicina (B Aires). 2021. 81(2). 191-197. English. PMID: 33906137.
133. Lin X., Zhu T., Xu F., Zhong J.Y., Li F., Shan S.K., Wu F., Guo B., Zheng M.H., Wang Y., Xu Q.S., Liao X.B., Lu H.Y., Xie X.B., Yuan L.Q. Plasma Exosomes Derived From Patients With End-Stage Renal Disease and Renal Transplant Recipients Have Different Effects on Vascular Calcification. Front. Cell. Dev. Biol. 2021 Jan 28. 8. 618228. doi: 10.3389/fcell.2020.618228. PMID: 33585452. PMCID: PMC7876285.
134. Düsing P., Zietzer A., Goody P.R., Hosen M.R., Kurts C., Nickenig G., Jansen F. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approa–ches. J. Mol. Med. (Berl.). 2021 Mar. 99(3). 335-348. doi: 10.1007/s00109-021-02037-7. Epub 2021 Jan 22. PMID: 33481059. PMCID: PMC7900031.
135. Chou P.R., Wu P.Y., Wu P.H., Huang T.H., Huang J.C., Chen S.C., Lee S.C., Kuo M.C., Chiu Y.W., Hsu Y.L., Chang J.M., Hwang S.J. Investigation of the Relationship between Cardiovascular Biomarkers and Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients. J. Pers. Med. 2022 Apr 15. 12(4). 636. doi: 10.3390/jpm12040636. PMID: 35455752. PMCID: PMC9025475.
136. Tiong M.K., Cai M.M.X., Toussaint N.D., Tan S.J., Pasch A., Smith E.R. Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Sci Rep. 2022 May 5. 12(1). 7358. doi: 10.1038/s41598-022-11065-3. PMID: 35513558. PMCID: PMC9072391.
137. Wu P.Y., Lee S.Y., Chang K.V., Chao C.T., Huang J.W. Gender-Related Differences in Chronic Kidney Disease-Associated Vascular Calcification Risk and Potential Risk Mediators: A Scoping Review. Healthcare (Basel). 2021 Aug 1. 9(8). 979. doi: 10.3390/healthcare9080979. PMID: 34442116. PMCID: PMC8394860.
138. Mohammed S.K., Taha E.M., Muhi S.A. A case-control study to determination FBXW7 and Fetuin-A levels in patients with type 2 diabetes in Iraq. J. Diabetes Metab. Disord. 2021 Jan 21. 20(1). 237-243. doi: 10.1007/s40200-021-00738-x. PMID: 34222065. PMCID: PMC8212217.
139. Uedono H., Mori K., Ochi A., Nakatani S., Miki Y., Tsuda A., Morioka T., Nagata Y., Imanishi Y., Shoji T., Inaba M., Emoto M. Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells. Sci Rep. 2021 Apr 5. 11(1). 7486. doi: 10.1038/s41598-021-86881-0. PMID: 33820929. PMCID: PMC8021573.
140. Piwkowska A., Zdrojewski Ł., Heleniak Z., Dębska-Ślizień A. Novel Markers in Diabetic Kidney Disease-Current State and Perspectives. Diagnostics (Basel). 2022 May 11. 12(5). 1205. doi: 10.3390/diagnostics12051205. PMID: 35626360.

Back to issue